As vaccine research continues to evolve, scientists are placing greater emphasis not only on antigen design but also on selecting adjuvants that can deliver stronger, more consistent immune respo...
The treatment of Alzheimer’s Disease (AD) has entered the era of "Disease-Modifying Therapies" (DMTs). With the approval of anti-Aβ monoclonal antibodies (such as Lecanemab), the Amyloid Cascade ...
In contemporary vaccine development, adjuvants are no longer optional components—they are strategic tools that define immunogenicity, dose efficiency, and long-term protection. Among naturally de...
